ReviewCancers2023
Surgical Management of Pancreatic Neuroendocrine Tumors.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Diagnostic performance of artificial intelligence versus conventional imaging for differentiating G2/G3 from G1 pancreatic neuroendocrine tumors: a systematic review and meta-analysis.BMC medical imaging · 2026Pooled it
- Surgical Versus Nonsurgical Management of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2025Pooled it
- Role of extracellular volume fraction determined by dual-layer spectral detector CT in predicting the tumor grade of pancreatic neuroendocrine neoplasms.Japanese journal of radiology · 2026Article
- Survival Outcomes in Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis of Progression-Related Endpoints.Cancers · 2026Review
- Ventricular fibrillation triggered by recurrent hypoglycemia in a patient with insulinoma associated with MEN1: case report and review of literature.Endocrine journal · 2026Review
- Advances in the management of neuroendocrine tumours: Evidence from a systematic review.Biomedical reports · 2026Article
- Article
- Endoscopic Ultrasound for the Management of Pancreatic Neuroendocrine Tumors: Diagnosis, Treatment, and Future Perspectives.Journal of gastroenterology and hepatology · 2026Review
- Pancreatic Neuroendocrine Tumors: From Benchside to Surgical Treatment.Medicina (Kaunas, Lithuania) · 2026Review
- Exploring the key molecular mechanisms and immune microenvironment of oxidative stress-related pathways in pancreatic neuroendocrine tumor combining scRNA-seq and bulk RNA.Discover oncology · 2026Article
- From diagnosis to treatment: navigating the course for pancreatic neuroendocrine neoplasms.Annals of medicine · 2025Review
- Diagnosis and Management of Functional Pancreatic Neuroendocrine Tumors in Children-A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- When is belzutifan the right option for von Hippel-Lindau disease-associated hemangioblastomas?-a critical review of LITESPARK-004 results.Translational cancer research · 2025Article
- Treatment of Pancreatic Neuroendocrine Tumors: Beyond Traditional Surgery and Targeted Therapy.Journal of clinical medicine · 2025Review
- The relationship between remnant cholesterol and WHO grade of pancreatic neuroendocrine neoplasms.Frontiers in endocrinology · 2025Article
- Article
- Surufatinib related nephrotic syndrome in a pancreatic neuroendocrine tumor: a case report and review of literature.Frontiers in oncology · 2025Article
- Case Report: A novel approach to pseudoportomesenteric hypertension with refractory chylothorax and ascites.Frontiers in gastroenterology (Lausanne, Switzerland) · 2025Article
- NON-FUNCTIONING SPORADIC PANCREATIC NEUROENDOCRINE TUMOR IS AN INDEPENDENT RISK FACTOR FOR RECURRENCE AFTER SURGICAL TREATMENT.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2025Article
- The association between non-HDL cholesterol and high-grade pancreatic neuroendocrine neoplasms.Endocrine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic neuroendocrine tumors (PNETs) are relatively uncommon malignancies, characterized as either functional or nonfunctional secondary to their secretion of biologically active hormones. A wide range of clinical behavior can be seen, with the primary prognostic indicator being tumor grade as defined by the Ki67 proliferation index and mitotic index. Surgery is the primary treatment modality for PNETs. While functional PNETs should undergo resection for symptom control as well as potential curative intent, nonfunctional PNETs are increasingly managed nonoperatively. There is increasing data to suggest small, nonfunctional PNETs (less than 2 cm) are appropriate follow with nonoperative active surveillance. Evidence supports surgical management of metastatic disease if possible, and occasionally even surgical management of the primary tumor in the setting of widespread metastases. In this review, we highlight the evolving surgical management of local and metastatic PNETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.